Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the thienopyran class of organic compounds. It is a nonphosphorus and nonpeptide inhibitor designed for high selectivity against protein tyrosine phosphatase 1B (PTP1B), an enzyme implicated in negative regulation of insulin signaling. The compound was developed through structure-based design to exploit unique features of PTP1B for selectivity and has been studied as a potential lead for antidiabetic drug development due to its ability to enhance insulin sensitivity by inhibiting PTP1B activity. Its molecular formula is C10H9NO6S and it has been characterized in structural biology studies as a highly selective low-molecular-weight inhibitor with no current clinical approval or marketed indications.[3][4][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(Oxalyl-amino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid.